Naoki Kamachi

663 total citations
24 papers, 367 citations indexed

About

Naoki Kamachi is a scholar working on Hepatology, Surgery and Oncology. According to data from OpenAlex, Naoki Kamachi has authored 24 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hepatology, 7 papers in Surgery and 7 papers in Oncology. Recurrent topics in Naoki Kamachi's work include Hepatocellular Carcinoma Treatment and Prognosis (22 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers) and Liver Disease and Transplantation (6 papers). Naoki Kamachi is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (22 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers) and Liver Disease and Transplantation (6 papers). Naoki Kamachi collaborates with scholars based in Japan. Naoki Kamachi's co-authors include Hironori Koga, Masahito Nakano, Hideki Iwamoto, Takashi Niizeki, Shigeo Shimose, Tomotake Shirono, Yu Noda, Ryoko Kuromatsu, Takuji Torimura and Shusuke Okamura and has published in prestigious journals such as Cancers, Frontiers in Oncology and Journal of Clinical Medicine.

In The Last Decade

Naoki Kamachi

24 papers receiving 363 citations

Peers

Naoki Kamachi
Fei Cao China
Yu-Jie Xu China
Xuqi Sun China
Gui‐Sheng Xie China
Hajime Aino Japan
Qiao Ke China
J. Zou United States
Hilda Wong China
Cheng‐Chung Tsai Taiwan
Yong‐Kang Diao China
Fei Cao China
Naoki Kamachi
Citations per year, relative to Naoki Kamachi Naoki Kamachi (= 1×) peers Fei Cao

Countries citing papers authored by Naoki Kamachi

Since Specialization
Citations

This map shows the geographic impact of Naoki Kamachi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoki Kamachi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoki Kamachi more than expected).

Fields of papers citing papers by Naoki Kamachi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoki Kamachi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoki Kamachi. The network helps show where Naoki Kamachi may publish in the future.

Co-authorship network of co-authors of Naoki Kamachi

This figure shows the co-authorship network connecting the top 25 collaborators of Naoki Kamachi. A scholar is included among the top collaborators of Naoki Kamachi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoki Kamachi. Naoki Kamachi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shirono, Tomotake, Hideki Iwamoto, Takashi Niizeki, et al.. (2022). Durable complete response is achieved by balloon‐occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatology Communications. 6(9). 2594–2604. 8 indexed citations
2.
Shimose, Shigeo, Hideki Iwamoto, Masatoshi Tanaka, et al.. (2022). Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study. Cancers. 14(17). 4284–4284. 11 indexed citations
3.
Kuromatsu, Ryoko, Tatsuya Ide, Shusuke Okamura, et al.. (2022). Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer. Cancers. 14(9). 2295–2295. 5 indexed citations
4.
Suzuki, Hiroyuki, Hideki Iwamoto, Shigeo Shimose, et al.. (2022). Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review. Frontiers in Oncology. 12. 948293–948293. 8 indexed citations
5.
Nakano, Masahito, Kazuta Fukumori, Yoichi Yano, et al.. (2021). Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers. 13(21). 5282–5282. 12 indexed citations
6.
7.
Kamachi, Naoki, Masahito Nakano, Shusuke Okamura, et al.. (2021). Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound. Cancer Reports. 5(2). e1471–e1471. 6 indexed citations
8.
Iwamoto, Hideki, Shigeo Shimose, Yu Noda, et al.. (2021). Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers. 13(11). 2786–2786. 39 indexed citations
9.
Shimose, Shigeo, Hideki Iwamoto, Masatoshi Tanaka, et al.. (2021). Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers. 13(1). 160–160. 37 indexed citations
10.
Niizeki, Takashi, Hideki Iwamoto, Tomotake Shirono, et al.. (2021). Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion. Cancers. 13(17). 4450–4450. 15 indexed citations
11.
Shirono, Tomotake, Takashi Niizeki, Hideki Iwamoto, et al.. (2021). Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. Journal of Clinical Medicine. 10(5). 987–987. 4 indexed citations
12.
Suzuki, Hiroyuki, Hideki Iwamoto, Masahito Nakano, et al.. (2021). Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments. Translational Oncology. 14(11). 101201–101201. 4 indexed citations
13.
Shimose, Shigeo, Hideki Iwamoto, Masatoshi Tanaka, et al.. (2021). Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival. Oncology. 99(12). 756–765. 2 indexed citations
14.
Nakano, Masahito, Ryoko Kuromatsu, Takashi Niizeki, et al.. (2021). Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma. ESMO Open. 6(1). 100020–100020. 15 indexed citations
15.
Nakano, Masahito, Ryoko Kuromatsu, Takashi Niizeki, et al.. (2020). Primary Treatment with Molecular‐Targeted Agents for Hepatocellular Carcinoma: A Propensity Score‐matching Analysis. Hepatology Communications. 4(8). 1218–1228. 18 indexed citations
16.
Shimose, Shigeo, Hideki Iwamoto, Takashi Niizeki, et al.. (2020). Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers. 12(7). 1867–1867. 54 indexed citations
17.
Iwamoto, Hideki, Hiroyuki Suzuki, Shigeo Shimose, et al.. (2020). Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events. Cancers. 12(4). 1010–1010. 44 indexed citations
18.
Shimose, Shigeo, Hideki Iwamoto, Masatoshi Tanaka, et al.. (2020). Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma. Oncology. 98(8). 558–565. 12 indexed citations
19.
Iwamoto, Hideki, Takashi Niizeki, Shigeo Shimose, et al.. (2019). Dose and Location of Irradiation Determine Survival for Patients with Hepatocellular Carcinoma with Macrovascular Invasion in External Beam Radiation Therapy. Oncology. 96(4). 192–199. 5 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fei Cao Breakdown of academic impact, for papers by Yu-Jie Xu Breakdown of academic impact, for papers by Xuqi Sun Breakdown of academic impact, for papers by Gui‐Sheng Xie Breakdown of academic impact, for papers by Hajime Aino Breakdown of academic impact, for papers by Qiao Ke Breakdown of academic impact, for papers by J. Zou Breakdown of academic impact, for papers by Hilda Wong Breakdown of academic impact, for papers by Cheng‐Chung Tsai Breakdown of academic impact, for papers by Yong‐Kang Diao
Rankless by CCL
2026